BAIYUNSHAN PH(00874),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

00874 BAIYUNSHAN PH

Closed Easter Monday 04-17 16:08:09

16.580

+0.060

+0.36%

High16.660	Low16.520	Vol290.00K
Open16.580	D1 Closing16.520	Amplitude0.85%
Mkt Cap26.96B	Tradable Cap3.65B	Total Shares1.63B
T/O4.81M	T/O Rate0.13%	Tradable Shares220.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"00874","market":"HK","secType":"STK","nameCN":"BAIYUNSHAN PH","latestPrice":16.58,"timestamp":1744877289026,"preClose":16.52,"halted":0,"volume":290000,"delay":0,"floatShares":220000000,"shares":1625790949,"eps":1.853935760304277,"marketStatus":"Closed Easter Monday","change":0.06,"latestTime":"04-17 16:08:09","open":16.58,"high":16.66,"low":16.52,"amount":4813160,"amplitude":0.008475,"askPrice":16.6,"askSize":2000,"bidPrice":16.58,"bidSize":22000,"shortable":3,"etf":0,"ttmEps":1.853935760304277,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":7,"adr":0,"listingDate":878140800000,"exchange":"SEHK","adjPreClose":16.52,"dividendRate":0.051302,"openAndCloseTimeList":[[1744853400000,1744862400000],[1744866000000,1744876800000]],"volumeRatio":0.419328195828445,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600332","market":"SH","secType":"STK","nameCN":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited","latestPrice":26.21,"timestamp":1744959600000,"preClose":26.29,"halted":0,"volume":2186600,"delay":0,"premium":"-40.49"}},"requestUrl":"/m/hq/s/00874","defaultTab":"news","newsList":[{"id":"2526553552","title":"Baiyunshan Pharmaceutical's Unit Amends Production License","url":"https://stock-news.laohu8.com/highlight/detail?id=2526553552","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526553552?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 18:08","pubTimestamp":1744279688,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical's  unit, Guangzhou Baiyunshan Mingxing Pharmaceutical, amended its production license after receiving approval from the Guangdong Provincial Medical Products Administration.The Chinese pharmaceutical company said it will add new production scopes and production lines, as well as confirm its compliance with good manufacturing practices or GMP, in the amended license.The new production address added to the license is No. 99, Jianxu 3rd Road, Baiyun District, Guangzhou, and the new production workshop is Manufacturing Department 8. The production line, which passed GMP standards, produces lyophilized powder injections for anti-tumor drugs.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["00874","BK0070","BK0196","BK1521","BK0096","BK0012","BK0097","BK1197","BK0175","BK1515","BK0028","600332","BK0183","BK1191","BK1606","BK0188","BK0239"],"gpt_icon":0},{"id":"2525252097","title":"Calculating The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525252097","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525252097?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 10:54","pubTimestamp":1743994466,"startTime":"0","endTime":"0","summary":"Key Insights Guangzhou Baiyunshan Pharmaceutical Holdings' estimated fair value is HK$17.82 based on 2 Stage Free Cash...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-874/guangzhou-baiyunshan-pharmaceutical-holdings-shares/news/calculating-the-intrinsic-value-of-guangzhou-baiyunshan-phar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["00874","BK1197","DCF","BK1515","BK1191","BK4211","BK4100","FCF","BK1606","BK1521","TV"],"gpt_icon":0},{"id":"2522689817","title":"Baiyunshan Pharma's Subsidiary Gets Nod to Trial Yupingfeng Tea Bag as Treatment For Hypothyroidism","url":"https://stock-news.laohu8.com/highlight/detail?id=2522689817","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522689817?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 12:27","pubTimestamp":1742963222,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical's  subsidiary, Guangzhou Baiyunshan Chen Li Ji Pharmaceutical Factory, received the Chinese drug administration's approval to conduct clinical trials on the Yupingfeng tea bag, according to a Shanghai Stock Exchange filing on Wednesday.The product will be tested as a treatment for Hashimoto's thyroiditis, subclinical hypothyroidism and clinical hypothyroidism patients who exhibit symptoms of spleen and lung Qi deficiency after LT4 treatment, the pharmaceutical company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["00874","BK1521","BK0196","BK0070","BK1606","BK0012","BK0097","BK0183","BK0188","BK0239","600332","BK1191","BK1197","BK0028","BK0096","BK0175","BK1515"],"gpt_icon":0},{"id":"2517268781","title":"Baiyunshan Pharmaceutical's Branch Gets Nod to Market Atorvastatin Calcium","url":"https://stock-news.laohu8.com/highlight/detail?id=2517268781","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517268781?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 12:26","pubTimestamp":1741321611,"startTime":"0","endTime":"0","summary":"A branch of Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874), Baiyunshan Chemical Pharmaceutical Factory, received the Chinese drug administration's approval to market atorvastatin calcium, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600332","BK0183","BK0070","BK0096","BK0012","BK1606","BK1521","BK0097","BK0188","BK1515","00874","BK0175","BK1197","BK0196","BK1191","BK0028","BK0239"],"gpt_icon":0},{"id":"2517049669","title":"Baiyunshan Pharma's Unit Gets Regulatory Nod to Amend License","url":"https://stock-news.laohu8.com/highlight/detail?id=2517049669","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517049669?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 12:32","pubTimestamp":1741235563,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical's  subsidiary, Guangzhou Baiyunshan Mingxing Pharmaceutical, obtained the Guangdong Provincial Drug Administration's approval to amend its license, according to a Shanghai Stock Exchange disclosure on Wednesday.The changes included amending the production address to Xiahengtian Industrial Zone, Shayong Village, Lishui Town, Nanhai District, Foshan City, China from No. 1, Jiantashan Road, Huangpu District, Guangzhou, China. The scope of the production was also lessened, the pharmaceutical company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0070","BK0183","BK0028","BK1521","BK1191","BK1606","600332","BK0097","BK0239","BK0175","BK0096","BK1197","BK0188","BK0012","BK0196","00874","BK1515"],"gpt_icon":0},{"id":"2516626639","title":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Low P/E No Reason For Excitement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516626639","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516626639?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 07:49","pubTimestamp":1741045747,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's ( HKG:874 ) price-to-earnings (or \"P/E\") ratio of 7.8x...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-874/guangzhou-baiyunshan-pharmaceutical-holdings-shares/news/guangzhou-baiyunshan-pharmaceutical-holdings-company-limited-16","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1606","BK1191","BK1197","00874","BK1515","BK1521"],"gpt_icon":0},{"id":"2514479312","title":"Guangzhou Baiyunshan Pharmaceutical - Disposal of Second New Underlying Assets of Gp Corp. to Industrial Securities Asset Management for RMB583.1 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514479312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514479312?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 16:32","pubTimestamp":1740731521,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2JL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0188","BK0239","BK1191","BK0070","00874","BK0028","BK0012","BK0196","BK1515","BK0096","BK0175","600332","BK1521","BK1606","BK0097","BK0183","BK1197"],"gpt_icon":0},{"id":"2511231691","title":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Received Written Resignation From Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2511231691","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511231691?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 23:18","pubTimestamp":1739546327,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Received Written Resignation From Executive DirectorFeb 14  - Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd 600332.SS:RECEIVED WRITTEN RESIGNATION FROM WU CHANGHAI AS EXECUTIVE DIRECTORFurther company coverage: 600332.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nFWN3P5160:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","BK0096","BK0196","BK0239","BK0097","BK1606","BK1191","BK0175","BK0183","600332","BK0012","BK1197","BK0028","BK1515","BK0188","00874","BK0070"],"gpt_icon":0},{"id":"2511668333","title":"Guangzhou Baiyunshan Pharmaceutical - Received Written Resignation From Wu Changhai as Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2511668333","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511668333?lang=en_us&edition=full_marsco","pubTime":"2025-02-14 18:07","pubTimestamp":1739527648,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250214:nFWN3P5160:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1521","BK0096","BK0196","BK0239","BK0097","BK1606","BK1191","BK0175","BK0183","600332","BK0012","BK1197","BK0028","BK1515","BK0188","00874","BK0070"],"gpt_icon":0},{"id":"2508466482","title":"Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2508466482","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508466482?lang=en_us&edition=full_marsco","pubTime":"2025-02-04 08:31","pubTimestamp":1738629068,"startTime":"0","endTime":"0","summary":"Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-874/guangzhou-baiyunshan-pharmaceutical-holdings-shares/news/guangzhou-baiyunshan-pharmaceutical-holdings-hkg874-has-a-pr-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["00874","BK1197","BK1515","BK1191","BK1606","BK1521","EBIT"],"gpt_icon":0},{"id":"2505270340","title":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Says Liu Juyan Resigns As Executive Director Of 9th Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2505270340","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505270340?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 23:37","pubTimestamp":1737473871,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Says Liu Juyan Resigns As Executive Director Of 9th SessionJan 21  - Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd 600332.SS:RECEIVED RESIGNATION FROM LIU JUYAN AS EXECUTIVE DIRECTOR OF 9TH SESSIONFurther company coverage: 600332.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH0NA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","600332","BK0097","BK1606","BK0096","BK0196","BK0239","BK0175","BK1191","BK0028","BK1515","BK0070","BK1521","BK0188","BK1197","00874","BK0012"],"gpt_icon":0},{"id":"2505474472","title":"Guangzhou Baiyunshan Pharmaceutical -  Received Resignation From Liu Juyan as Executive Director of 9TH Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2505474472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505474472?lang=en_us&edition=full_marsco","pubTime":"2025-01-21 18:44","pubTimestamp":1737456289,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nFWN3OH0NA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["600332","BK0070","BK1521","BK1606","BK0188","BK0028","BK1197","BK0183","BK0097","BK0096","BK0175","BK1191","BK1515","BK0196","00874","BK0239","BK0012"],"gpt_icon":0},{"id":"2501795426","title":"Baiyunshan Pharma's Venture Capital Fund Completes Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2501795426","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501795426?lang=en_us&edition=full_marsco","pubTime":"2025-01-08 11:58","pubTimestamp":1736308724,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical  said the 400 million yuan venture capital fund it invested in completed its industrial and commercial registration, according to a Shanghai Stock Exchange disclosure on Tuesday.The fund, Guangzhou Guangyao Industrial Investment Venture Capital Fund Partnership , completed the filing procedures with the Asset Management Association of China, the pharmaceutical company said.Baiyunshan Pharma's Shanghai shares slipped more than 1% and Hong Kong shares fell less than 2% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0070","00874","BK0028","BK0188","BK1521","BK0097","BK1191","BK1197","BK1606","BK0196","600332","BK0239","BK0096","BK0183","BK0175","BK0012","BK1515"],"gpt_icon":0},{"id":"2501627135","title":"There Are Reasons To Feel Uneasy About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2501627135","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501627135?lang=en_us&edition=full_marsco","pubTime":"2025-01-07 13:23","pubTimestamp":1736227398,"startTime":"0","endTime":"0","summary":"If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-874/guangzhou-baiyunshan-pharmaceutical-holdings-shares/news/there-are-reasons-to-feel-uneasy-about-guangzhou-baiyunshan","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["00874","BK1521","BK1606","EBIT","BK1191","BK1197","BK1515"],"gpt_icon":0},{"id":"2493764896","title":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Proposes To Appoint Li Xiaojun As An Executive Director Of 9Th Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2493764896","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493764896?lang=en_us&edition=full_marsco","pubTime":"2024-12-23 23:32","pubTimestamp":1734967923,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Baiyunshan Pharmaceutical Proposes To Appoint Li Xiaojun As An Executive Director Of 9Th SessionDec 23  - Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd 600332.SS:PROPOSES TO APPOINT LI XIAOJUN AS AN EXECUTIVE DIRECTOR OF 9TH SESSIONPROPOSES TO APPOINT LI XIAOJUN AS EXECUTIVE DIRECTORFurther company coverage: 600332.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NM02Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK1515","BK1606","00874","BK0097","BK0096","BK1197","BK0070","BK1521","BK0012","BK0175","BK0183","BK0028","BK0188","BK1191","BK0239","600332"],"gpt_icon":0},{"id":"2493375347","title":"Guangzhou Baiyunshan Pharmaceutical - Proposes to Appoint Li Xiaojun as Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2493375347","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493375347?lang=en_us&edition=full_marsco","pubTime":"2024-12-23 19:29","pubTimestamp":1734953391,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NM02Q:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","BK1606","BK0196","00874","BK0183","BK0096","BK0188","600332","BK0097","BK0012","BK1191","BK0028","BK0070","BK1515","BK1521","BK0175","BK1197"],"gpt_icon":0},{"id":"2492822509","title":"Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) stock most popular amongst private companies who own 46%, while individual investors hold 36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492822509","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492822509?lang=en_us&edition=full_marsco","pubTime":"2024-12-17 10:19","pubTimestamp":1734401966,"startTime":"0","endTime":"0","summary":"Key Insights Guangzhou Baiyunshan Pharmaceutical Holdings' significant private companies ownership suggests that the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-874/guangzhou-baiyunshan-pharmaceutical-holdings-shares/news/guangzhou-baiyunshan-pharmaceutical-holdings-company-limited-15","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1606","BK1191","BK1197","00874","BK1515","BK1521"],"gpt_icon":0},{"id":"2491763342","title":"Baiyunshan Pharmaceutical's Unit Gets Nod to Cefuroxime Sodium for Injection's Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2491763342","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491763342?lang=en_us&edition=full_marsco","pubTime":"2024-12-16 12:18","pubTimestamp":1734322688,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical's  unit, Guangzhou Baiyunshan Tianxin Pharmaceutical, received approval from the Chinese drug regulator to make changes for its cefuroxime sodium for injection after it passed the regulator's consistency evaluation, according to a Shanghai Stock Exchange disclosure on Dec. 13.The changes included amending the supplier of the drug's raw materials, the drug's quality standards, and the drug's packaging materials and containers, the pharmaceutical company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1521","BK0096","BK0196","BK0239","BK0097","BK1606","BK1191","BK0175","BK0183","600332","BK0012","BK1197","BK0028","BK1515","BK0188","00874","BK0070"],"gpt_icon":0},{"id":"2486356873","title":"Baiyunshan Pharma's Unit Gets Nod to Make Changes to Selaginella Jiangnanensis Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2486356873","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486356873?lang=en_us&edition=full_marsco","pubTime":"2024-11-28 12:23","pubTimestamp":1732767794,"startTime":"0","endTime":"0","summary":"The Chinese drug administration approved the supplementary application of Guangzhou Baiyunshan Pharmaceutical's  unit, Baiyunshan Pharmaceutical General Factory, to make changes to selaginella jiangnanensis tablets' instructions, according to a Shanghai Stock Exchange filing on Wednesday.The changes included safety instructions for the drug's usage and other details, the pharmaceutical company said.The drug is used for subcutaneous purpura caused by blood heat.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600332","BK0070","BK1521","BK1606","BK0188","BK0028","BK1197","BK0183","BK0097","BK0096","BK0175","BK1191","BK1515","BK0196","00874","BK0239","BK0012"],"gpt_icon":0},{"id":"2486353217","title":"Baiyunshan Pharma Gets Nod to Market Anti-Tumor Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2486353217","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486353217?lang=en_us&edition=full_marsco","pubTime":"2024-11-28 12:11","pubTimestamp":1732767101,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) received approval from the Chinese drug administration to market its active pharmaceutical ingredient, sunitinib malate, according to a Shang","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600332","BK0175","BK1197","BK0196","BK1521","BK0028","BK0070","BK1191","BK0096","BK0188","BK1515","00874","BK0183","BK0239","BK0097","BK1606","BK0012"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gybys.com.cn","stockEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":-0.0654},{"period":"3month","weight":-0.0438},{"period":"6month","weight":-0.1471},{"period":"1year","weight":-0.1134},{"period":"ytd","weight":-0.089}],"compareEarnings":[{"period":"1week","weight":0.0345},{"period":"1month","weight":-0.1352},{"period":"3month","weight":0.0925},{"period":"6month","weight":0.0284},{"period":"1year","weight":0.3165},{"period":"ytd","weight":0.0666}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd i is engaged in the pharmaceutical and healthcare industry. The Company's segments are Great Southern TCM, Great Commerce, Great Health and Great Medical Care. The Company's Great South TCM includes research, development, manufacturing and sales for Chinese and western medicine, chemical raw medicine, natural drug, biological medicine and intermediates of chemical raw medicine. The Company's Great Health segment includes the research, development, manufacturing and sales of beverages, foods, health products and other products. The Company's Great Commerce segment includes wholesale, retail, import and export for western medicine, Chinese medicine and medical apparatus and instruments. The Great Medical segment is engaged in medical services, traditional Chinese medicine health preservation, modern pension and medical equipment industry.","yearOnYearQuotes":[{"month":1,"riseRate":0.407407,"avgChangeRate":-0.012989},{"month":2,"riseRate":0.703704,"avgChangeRate":0.060371},{"month":3,"riseRate":0.607143,"avgChangeRate":0.055829},{"month":4,"riseRate":0.642857,"avgChangeRate":0.083917},{"month":5,"riseRate":0.555556,"avgChangeRate":0.049452},{"month":6,"riseRate":0.481481,"avgChangeRate":0.021437},{"month":7,"riseRate":0.407407,"avgChangeRate":-0.018239},{"month":8,"riseRate":0.37037,"avgChangeRate":-0.039061},{"month":9,"riseRate":0.407407,"avgChangeRate":-0.011257},{"month":10,"riseRate":0.407407,"avgChangeRate":0.002825},{"month":11,"riseRate":0.428571,"avgChangeRate":0.008626},{"month":12,"riseRate":0.555556,"avgChangeRate":0.026748}],"exchange":"SEHK","name":"BAIYUNSHAN PH","nameEN":"BAIYUNSHAN PH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BAIYUNSHAN PH(00874),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BAIYUNSHAN PH(00874) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BAIYUNSHAN PH,00874,BAIYUNSHAN PH股票,BAIYUNSHAN PH股票老虎,BAIYUNSHAN PH股票老虎国际,BAIYUNSHAN PH行情,BAIYUNSHAN PH股票行情,BAIYUNSHAN PH股价,BAIYUNSHAN PH股市,BAIYUNSHAN PH股票价格,BAIYUNSHAN PH股票交易,BAIYUNSHAN PH股票购买,BAIYUNSHAN PH股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BAIYUNSHAN PH(00874),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BAIYUNSHAN PH(00874) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}